NASDAQ:KALV
KalVista Pharmaceuticals Inc Stock News
$12.13
-0.0400 (-0.329%)
At Close: May 03, 2024
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
KalVista Pharmaceuticals (KALV) Receives a Buy from Needham
08:12pm, Tuesday, 10'th Mar 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on KalVista Pharmaceuticals (
KALV
–
Research Report
) today and set a price target of
$28.00
. The company’s shares closed last Monday at $1
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
11:30am, Tuesday, 10'th Mar 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provide
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y
07:25pm, Friday, 21'st Feb 2020
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line
03:22pm, Friday, 21'st Feb 2020
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
KalVista Pharmaceuticals to Present at SVB Leerink 9th Annual Global Healthcare Conference
12:30pm, Wednesday, 19'th Feb 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
02:46pm, Tuesday, 18'th Feb 2020
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4
03:30pm, Thursday, 13'th Feb 2020
Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.
New Covid-19 Cases Increase, 5 Defensive Stocks to Buy
03:03pm, Thursday, 13'th Feb 2020
Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
02:45pm, Wednesday, 12'th Feb 2020
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
02:45pm, Wednesday, 12'th Feb 2020
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened.
08:35pm, Tuesday, 11'th Feb 2020
Pfizer and Merck are each cutting ties with a smaller clinical-stage biotech after experimental drugs being developed under separate alliances fell short
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN )
KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs
09:30pm, Monday, 10'th Feb 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc
Is KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Overpaid Relative To Its Peers?
01:35pm, Wednesday, 05'th Feb 2020
In 2016 Andy Crockett was appointed CEO of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV). This analysis aims first to...
